Latest news with #TreaceMedicalConcepts
Yahoo
2 days ago
- Business
- Yahoo
Treace Medical Concepts, Inc. (NASDAQ:TMCI) is favoured by institutional owners who hold 53% of the company
Institutions' substantial holdings in Treace Medical Concepts implies that they have significant influence over the company's share price 52% of the business is held by the top 7 shareholders 25% of Treace Medical Concepts is held by insiders Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. If you want to know who really controls Treace Medical Concepts, Inc. (NASDAQ:TMCI), then you'll have to look at the makeup of its share registry. We can see that institutions own the lion's share in the company with 53% ownership. Put another way, the group faces the maximum upside potential (or downside risk). Since institutional have access to huge amounts of capital, their market moves tend to receive a lot of scrutiny by retail or individual investors. As a result, a sizeable amount of institutional money invested in a firm is generally viewed as a positive attribute. Let's take a closer look to see what the different types of shareholders can tell us about Treace Medical Concepts. Check out our latest analysis for Treace Medical Concepts Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices. We can see that Treace Medical Concepts does have institutional investors; and they hold a good portion of the company's stock. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Treace Medical Concepts, (below). Of course, keep in mind that there are other factors to consider, too. Since institutional investors own more than half the issued stock, the board will likely have to pay attention to their preferences. It looks like hedge funds own 9.9% of Treace Medical Concepts shares. That worth noting, since hedge funds are often quite active investors, who may try to influence management. Many want to see value creation (and a higher share price) in the short term or medium term. With a 19% stake, CEO John Treace is the largest shareholder. Armistice Capital LLC is the second largest shareholder owning 9.9% of common stock, and BlackRock, Inc. holds about 6.1% of the company stock. We also observed that the top 7 shareholders account for more than half of the share register, with a few smaller shareholders to balance the interests of the larger ones to a certain extent. Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. Quite a few analysts cover the stock, so you could look into forecast growth quite easily. While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO. Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group. Our information suggests that insiders maintain a significant holding in Treace Medical Concepts, Inc.. Insiders own US$86m worth of shares in the US$343m company. It is great to see insiders so invested in the business. It might be worth checking if those insiders have been buying recently. The general public-- including retail investors -- own 12% stake in the company, and hence can't easily be ignored. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies. I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. Consider risks, for instance. Every company has them, and we've spotted 1 warning sign for Treace Medical Concepts you should know about. If you would prefer discover what analysts are predicting in terms of future growth, do not miss this free report on analyst forecasts. NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures. — Investing narratives with Fair Values Vita Life Sciences Set for a 12.72% Revenue Growth While Tackling Operational Challenges By Robbo – Community Contributor Fair Value Estimated: A$2.42 · 0.1% Overvalued Vossloh rides a €500 billion wave to boost growth and earnings in the next decade By Chris1 – Community Contributor Fair Value Estimated: €78.41 · 0.1% Overvalued Intuitive Surgical Will Transform Healthcare with 12% Revenue Growth By Unike – Community Contributor Fair Value Estimated: $325.55 · 0.6% Undervalued View more featured narratives — Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
05-06-2025
- Business
- Yahoo
Treace Files Patent Infringement Suit Against Zimmer Biomet to Protect Lapiplasty® Bunion Technology
PONTE VEDRA, Fla., June 05, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ('Treace' or the 'Company') (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® procedures, today announced that it filed a lawsuit against Zimmer Biomet Holdings, Inc. and Paragon 28, Inc. (collectively, 'Zimmer') (NYSE: ZBH), alleging infringement of 4 patents related to Treace's innovative Lapiplasty® 3D Bunion Correction® technologies. The suit was filed in the United States District Court for the District of Delaware, and seeks injunctive relief and damages. 'Treace Medical was the first company to develop, patent, and introduce an instrumented 3D bunion correction system for true tri-planar lapidus bunion correction and is the recognized leader in the surgical treatment of bunions. We believe that this lawsuit is necessary to protect the significant investments we have made in our pioneering research and technology, which is in the best interest of our stockholders,' said John T. Treace, Chairman, CEO and Founder of Treace. 'Enforcing and defending our intellectual property helps to drive our ability to continue to innovate solutions that benefit patients.' Treace's patent portfolio includes 80 granted U.S. patents, with an additional 26 granted patents worldwide and over 150 pending patent applications. About Treace Medical Concepts Treace Medical Concepts, Inc. is a medical technology company with the goal of advancing the standard of care for the surgical management of bunion and related midfoot deformities. Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot and affect approximately 67 million Americans, of which Treace estimates 1.1 million are annual surgical candidates. Treace has pioneered and patented the Lapiplasty® 3D Bunion Correction® System – a combination of instruments, implants, and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. To further support the needs of bunion patients, Treace has introduced its Adductoplasty® Midfoot Correction System, designed for reproducible surgical correction of midfoot deformities, the SpeedMTP™ Rapid Compression Implant for addressing bunions through big toe joint fusions, and two systems for minimally invasive osteotomy surgeries: the Nanoplasty™ 3D Minimally Invasive Bunion Correction System and the Percuplasty™ Percutaneous 3D Bunion Correction System. The Company continues to expand its footprint in the foot and ankle market with the introduction of its SpeedPlate™ Rapid Compression Implants, an innovative fixation platform with broad versatility across Lapiplasty® and Adductoplasty® procedures, as well as other common bone fusion procedures of the foot. For more information, please visit To learn more about Treace, connect with us on LinkedIn, X, Facebook and Instagram. Contacts:Treace Medical ConceptsMark L. HairChief Financial Officermhair@ 373-5940 Investors:Gilmartin GroupPhilip Trip Taylor IR@
Business Wire
02-06-2025
- Business
- Business Wire
TMCI截止日期：Rosen Law Firm敦促損失超過10萬美元的Treace Medical Concepts, Inc. (NASDAQ: TMCI)股東與法律事務所聯絡以瞭解有關其權利的資訊
紐約--(BUSINESS WIRE)--(美國商業資訊)-- 全球性投資人權益法律事務所Rosen Law Firm提醒投資人，一名股東代表在2023年5月8日至2024年5月7日期間購買Treace Medical Concepts, Inc. (NASDAQ: TMCI)證券的投資人提起了集體訴訟。Treace Medical自稱是一家「專注於提升拇趾滑液囊炎及相關中足畸形外科治療護理標準的醫療科技公司」。 如欲瞭解更多資訊，請遞交 表格 、向Phillip Kim律師 寄送電子郵件 ，或致電866-767-3653聯絡我們。 指控內容：Rosen Law Firm正在調查對Treace Medical Concepts, Inc. (NASDAQ: TMCI)在其業務營運方面誤導投資人的指控。 起訴書指稱，在集體訴訟期內，被告做出了虛假和/或誤導性陳述及/或未揭露：(1)競爭影響了其主要產品Lapiplasty 3D拇趾滑液囊炎矯正系統(Lapiplasty)的市場需求和使用率；(2)因此，Treace Medical的營收出現下降，且Treace Medical需要加快推出一款可替代截骨術（一種透過切割和重新對齊骨骼以改善其位置或功能的外科手術）的產品；以及(3)被告關於Treace Medical的業務、營運和前景的正面陳述具有重大誤導性和/或缺乏合理依據。訴訟稱，當市場瞭解真實詳情後，投資人蒙受了損失。 現在怎麼辦：您可能有資格參與針對Treace Medical Concepts, Inc.的集體訴訟。如果有股東希望擔任該集體訴訟的原告代表，則必須在2025年6月10日之前向法院提出申請。原告代表是指代表其他集體訴訟成員主導訴訟的當事人代表。您無需參與此案即有資格獲得追償。如果您選擇不採取任何行動，您也可以保持缺席集體訴訟成員的身分。如欲瞭解更多資訊，請點選 此處 。 所有代理均為勝訴後取酬。股東無需支付任何費用或開支。 關於Rosen Law Firm：與Rosen Law Firm不同，一些就此等事宜發表公告的法律事務所並不會實際提起證券集體訴訟。身為股東權益訴訟領域公認的領導者， Rosen Law Firm 一直致力於協助股東挽回損失、改善公司治理結構，並追究公司高階主管的違法行為責任。自成立以來，Rosen Law Firm已經為股東挽回了超過10億美元的損失。 請在LinkedIn： 、Twitter： 或Facebook： 上關注我們，以瞭解最新情況。 律師廣告。先前案例不保證可獲致類似結果。 免責聲明：本公告之原文版本乃官方授權版本。譯文僅供方便瞭解之用，煩請參照原文，原文版本乃唯一具法律效力之版本。
Business Wire
01-06-2025
- Business
- Business Wire
TMCI Deadline: Rosen Law Firm Urges Treace Medical Concepts, Inc. (NASDAQ: TMCI) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of purchasers of securities of Treace Medical Concepts, Inc. (NASDAQ: TMCI) between May 8, 2023 and May 7, 2024. Treace Medical describes itself as a 'medical technology company focused on advancing the standard of care for the surgical management of bunion and related midfoot deformities.' For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Firm is Investigating the Allegations that Treace Medical Concepts, Inc. (NASDAQ: TMCI) Misled Investors Regarding its Business Operations. According to the lawsuit, during the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) competition impacted the demand for and utilization of its primary product, the Lapiplasty 3D Bunion Correction System (the 'Lapiplasty'); (2) as a result, Treace Medical's revenue declined and Treace Medical needed to accelerate its plans to offer a product that was an alternative to osteotomy (a surgical procedure that involves cutting and realigning a bone to improve its position or function); and (3) defendants' positive statements about Treace Medical's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages. What Now: You may be eligible to participate in the class action against Treace Medical Concepts, Inc. Shareholders who want to serve as lead plaintiff for the class must file their motions with the court by June 10, 2025. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here. All representation is on a contingency fee basis. Shareholders pay no fees or expenses. About Rosen Law Firm: Some law firms issuing releases about this matter do not actually litigate securities class actions. Rosen Law Firm does. Rosen Law Firm is a recognized leader in shareholder rights litigation, dedicated to helping shareholders recover losses, improving corporate governance structures, and holding company executives accountable for their wrongdoing. Since its inception, Rosen Law Firm has obtained over $1 billion for shareholders. Follow us for updates on LinkedIn: on Twitter: or on Facebook: Attorney Advertising. Prior results do not guarantee a similar outcome.
Associated Press
04-05-2025
- Business
- Associated Press
TMCI Investors are Urged to Contact Robbins LLP for Information About the Treace Medical Concepts, Inc. Class Action Lawsuit
SAN DIEGO, CA - May 3, 2025 ( NEWMEDIAWIRE ) - Robbins LLP reminds stockholders that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Treace Medical Concepts, Inc. (NASDAQ: TMCI) securities between May 8, 2023 and May 7, 2024. The Company is focused on advancing the standard of care for the surgical management of bunion and related midfoot deformities. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Allegations that Treace Medical Concepts, Inc. (TMCI) Misled Investors Regarding Demand for its Primary Product According to the complaint, during the class period, defendants failed to disclose that (1) competition impacted the demand for and utilization of its primary product, the Lapiplasty 3D Bunion Correction System, and (2) as a result, Treace Medical's revenue declined and the Company needed to accelerate its plans to offer a product that was an alternative to osteotomy (a surgical procedure that involves cutting and realigning a bone to improve its position or function). Plaintiff alleges that when the truth was revealed, the price of Treace Medical's stock fell nearly 63%, to close at $4.17 per share on May 8, 2024. What Now: You may be eligible to participate in the class action against Treace Medical Concepts, Inc. Shareholders who want to serve as lead plaintiff for the class must file their papers with the court by June 10, 2025. The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here. All representation is on a contingency fee basis. Shareholders pay no fees or expenses. About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Treace Medical Concepts, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today. Attorney Advertising. Past results do not guarantee a similar outcome. Contact: Aaron Dumas, Jr. Robbins LLP 5060 Shoreham Pl., Ste. 300 San Diego, CA 92122 [email protected] (800) 350-6003
